Niclas Jonsson, Ph.D.

Scientific Director & Pharmacometrics Platform Scientific Lead

Portrait-of-Niclas-Jonsson-Pharmetheus

Bio

  • Co-founded Pharmetheus in 2012, actively working in client projects, serving as Scientific Director, deputy Chief Research Officer, and Pharmacometrics Platform Scientific Lead
  • Expertise includes pharmacometrics and its applications across therapeutic areas
  • Previously worked as Senior Consultant at Exprimo NV, Sweden, where he interacted with clients and provided pharmacokinetic, pharmacodynamic, and disease modeling and simulation services to drug development programs in various therapeutic areas, as Global Head of Modeling and Simulation at Hoffman-La Roche, Switzerland, Associate Professor of Applied Pharmacometrics and Senior Lecturer at Uppsala University, and as Postdoctoral Researcher at University of California San Francisco, USA. Co-developer of the software programs Xpose 4 and PsN
  • M.Sc. in Pharmacy (1991) and Ph.D. in Biopharmaceutical Sciences (1998) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

The reference corrected VPC (rcVPC) – an informative model diagnostics for assessing underying exposure-response relationshipsThe impact of misspecified covariate models on inclusion and omission bias when using FREM and FFEMPopulation pharmacokinetic and dose–response models of nepadutant, a selective antagonist of the NK₂ receptors, in infants with colicFull random effects models (FREM): A practical usage guideGenerating uncertainty estimates in empirical forest plotsThe reference corrected VPC – A more intuitive model diagnosticUsing forest plots to interpret covariate effects in pharmacometric modelsProperties of the full random-effect modeling approach with missing covariate dataEfficient and relevant stepwise covariate model building for pharmacometrics [2]Checklists and best practices to support the informed use of Forest plots to illustrate the impact of covariates in pharmacometric modelsWriting reports of modelling and simulation analysis: Our experience in the field of pharmacometrics